Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Effect on Body Weight of Recombinant-Methionyl Human Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00392925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Effect on Body Weight of Recombinant-Methionyl Human Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
September 30, 2007
Enrollment
177 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight